MarketBeat Compares ADMA Biologics and Werewolf Therapeutics Financial Profiles

MarketBeat published an analysis comparing two healthcare companies, ADMA Biologics and Werewolf Therapeutics, across several financial metrics. The comparison covered profitability, risk, institutional ownership, dividends, analyst recommendations, valuation, and earnings. Specific findings noted that ADMA Biologics has higher revenue and earnings, while Werewolf Therapeutics is trading at a lower price-to-earnings ratio. Regarding risk, ADMA Biologics has a beta of 0.78, whereas Werewolf Therapeutics has a beta of 0.51.

The report details the ownership structures of both companies, noting that 75.7% of ADMA Biologics shares are held by institutional investors, compared to 64.8% for Werewolf Therapeutics. The data provides investors with comparative metrics on market exposure and company valuation.